[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Melnik BC, Schmitz G, Zouboulis CC: Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol; 2009 Aug;129(8):1868-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-acne agents attenuate FGFR2 signal transduction in acne.
  • Increased fibroblast growth factor receptor-2 (FGFR2) signaling has been proposed to be involved in acne pathogenesis and explains acne lesions in Apert syndrome and unilateral acneiform nevus associated with gain-of-function point mutations of FGFR2.
  • If, indeed, increased FGFR2 signaling plays a major pathogenic role in follicular hyperkeratinization and sebaceous gland hypertrophy in acne, effective anti-acne drugs may attenuate increased FGFR2 signaling.
  • The purpose of this article is to elucidate the hypothesis that known anti-acne agents may operate by downregulation of increased FGFR2 signaling.
  • Erythromycin, a P-450 inhibitor, may interfere with FGFR2 signaling by its inhibitory effect on retinoid catabolism.
  • The gain-of-function mutations of FGFR2 in Apert syndrome and unilateral acneiform nevus, and the proposed synergistic inhibitory interactions of anti-acne agents at various levels of the FGFR2-signaling cascade underline the role of FGFR2 signaling in the pathogenesis of acne.
  • [MeSH-major] Acne Vulgaris / drug therapy. Receptor, ErbB-2 / antagonists & inhibitors. Signal Transduction / drug effects
  • [MeSH-minor] Androgen Antagonists / pharmacology. Benzoyl Peroxide / pharmacology. Dicarboxylic Acids / pharmacology. Erythromycin / pharmacology. Humans. Interleukin-1alpha / biosynthesis. Isotretinoin / pharmacology. Reactive Oxygen Species. Tetracyclines / pharmacology. Tretinoin / pharmacology. alpha-MSH / pharmacology


2. Melnik BC: Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol; 2009 May;1(3):141-56
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of FGFR2-signaling in the pathogenesis of acne.
  • It is the purpose of this review to extend our understanding of the fibroblast growth factor (FGF) receptor-2b-signaling network in the pathogenesis of acne.
  • A new concept of the role of FGFR2b-signaling in dermal-epithelial interaction for skin appendage formation, pilosebaceous follicle homeostasis, comedogenesis, sebaceous gland proliferation and lipogenesis is presented.
  • The FGFR2-gain-of-function mutations in Apert syndrome and unilateral acneiform nevus are most helpful model diseases pointing the way to androgen-dependent dermalepithelial FGFR2-signaling in acne.
  • Androgen-mediated upregulation of FGFR2b-signaling in acne-prone skin appears to be involved in the pathogenesis of acne vulgaris.
  • Postnatal deletion of FGFR2b in mice resulted in severe sebaceous gland atrophy.
  • The importance of FGFR2b in sebaceous gland physiology is further supported by the mode of action of anti-acne agents which have been proposed to attenuate FGFR2b-signaling.
  • Downregulation of FGFR2b-signaling by isotretinoin explains its therapeutic effect in acne.
  • Insulin-like growth factor-1 (IGF-1), the mediator of growth hormone during puberty, intracts with androgen-dependent FGFR2b-signaling and links androgen- and FGF-mediated signal transduction important in sebaceous gland homeostasis.
  • The search for a follicular defect in the dermalepithelial regulation of growth factor-signaling in acne-prone skin appears to be a most promising approach to clarify the pathogenesis of acne.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2178-89 [16575387.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):750-8 [16582625.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6283-98 [16880536.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2322-5 [16955133.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7329-38 [17202144.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1697-706 [17218409.001]
  • [Cites] Bioorg Med Chem. 2007 Mar 15;15(6):2368-74 [17267227.001]
  • [Cites] Horm Metab Res. 2007 Feb;39(2):136-40 [17326009.001]
  • [Cites] Biochem J. 2007 May 1;403(3):369-79 [17419683.001]
  • [Cites] Pediatr Dermatol. 2007 Mar-Apr;24(2):186-8 [17461821.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11999-2004 [17626181.001]
  • [Cites] Dermatol Clin. 2007 Oct;25(4):477-85, vii [17903607.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1286-93 [17989724.001]
  • [Cites] Mol Cancer. 2007;6:82 [18157915.001]
  • [Cites] Biochem J. 2008 Jul 1;413(1):37-49 [18373495.001]
  • [Cites] Mol Nutr Food Res. 2008 Jun;52(6):718-26 [18496812.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):979-81 [18647304.001]
  • [Cites] J Dtsch Dermatol Ges. 2009 Jun;7 Suppl 4:1-263 [19522919.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]
  • [Cites] Development. 2005 Apr;132(7):1737-48 [15753216.001]
  • [Cites] Birth Defects Orig Artic Ser. 1978;14(6B):341-60 [728574.001]
  • [Cites] J Endocrinol. 1976 Dec;71(3):279-88 [1003058.001]
  • [Cites] J Endocrinol. 1975 Mar;64(3):503-10 [1133539.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):246-50 [1309608.001]
  • [Cites] Br J Dermatol. 1992 Dec;127(6):585-8 [1476918.001]
  • [Cites] Pediatr Dermatol. 1992 Sep;9(3):298-300 [1488385.001]
  • [Cites] Mol Endocrinol. 1992 Dec;6(12):2123-8 [1491693.001]
  • [Cites] J Invest Dermatol. 1992 Jun;98(6):895-901 [1534342.001]
  • [Cites] J Invest Dermatol. 1988 Dec;91(6):566-71 [2461419.001]
  • [Cites] Cell Regul. 1989 Nov;1(1):87-97 [2519621.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):315-6 [2527875.001]
  • [Cites] Gynecol Obstet Invest. 1986;22(4):206-11 [2950033.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):837-41 [3162101.001]
  • [Cites] Endocrinology. 1988 Mar;122(3):1159-64 [3342749.001]
  • [Cites] J Craniofac Genet Dev Biol. 1986;6(2):99-112 [3459732.001]
  • [Cites] Am J Dis Child. 1987 May;141(5):562-4 [3578171.001]
  • [Cites] J Invest Dermatol. 1969 Jan;52(1):32-6 [4236132.001]
  • [Cites] Arch Dermatol. 1970 Oct;102(4):381-5 [4248541.001]
  • [Cites] Arch Dermatol Forsch. 1971;242(1):12-29 [4258128.001]
  • [Cites] Br J Dermatol. 1974 Jun;90(6):623-30 [4277343.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):193-5 [4281326.001]
  • [Cites] N Engl J Med. 1983 Apr 28;308(17):981-6 [6220224.001]
  • [Cites] Am J Dermatopathol. 1984 Jun;6(3):213-20 [6233909.001]
  • [Cites] Cutis. 1980 May;25(5):538-40 [6445815.001]
  • [Cites] Arch Dermatol. 1982 Mar;118(3):206-8 [6461294.001]
  • [Cites] Biochem Pharmacol. 1984 Jan 1;33(1):103-8 [6704136.001]
  • [Cites] Arch Dermatol Res. 1982;272(3-4):343-9 [7165343.001]
  • [Cites] Horm Res. 1994;42(1-2):49-54 [7525445.001]
  • [Cites] Am J Med Genet. 1995 Jul 31;58(1):94-6 [7573165.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):126-38 [7589793.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):145-54 [7604876.001]
  • [Cites] J Dermatol. 1995 Apr;22(4):249-52 [7608381.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):209-14 [7636302.001]
  • [Cites] Br J Dermatol. 1995 Jan;132(1):139-43 [7756126.001]
  • [Cites] Science. 1994 Nov 4;266(5186):819-22 [7973639.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1048-56 [7977638.001]
  • [Cites] Hum Mol Genet. 1995 Jul;4(7):1229-33 [8528214.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jan 26;218(3):688-93 [8579575.001]
  • [Cites] J Invest Dermatol. 1996 Jan;106(1):176-82 [8592071.001]
  • [Cites] Nature. 1996 Feb 8;379(6565):557-60 [8596637.001]
  • [Cites] Exp Dermatol. 1995 Dec;4(6):335-41 [8608340.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):977-89 [8622701.001]
  • [Cites] Am J Hum Genet. 1996 May;58(5):923-32 [8651276.001]
  • [Cites] Nat Genet. 1996 May;13(1):48-53 [8673103.001]
  • [Cites] Br J Dermatol. 1996 Feb;134(2):247-56 [8746337.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):179-89 [9042154.001]
  • [Cites] Cell. 1997 May 30;89(5):693-702 [9182757.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):261-6 [9299490.001]
  • [Cites] Cell. 1997 Dec 12;91(6):789-98 [9413988.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1642-55 [9501086.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):235-53 [9516079.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):410-5 [9540984.001]
  • [Cites] Dermatology. 1998;196(1):38-42 [9557222.001]
  • [Cites] Dermatology. 1998;196(1):98-9 [9557240.001]
  • [Cites] Dermatology. 1998;196(1):171-5 [9557256.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3966-73 [9632781.001]
  • [Cites] Hum Mol Genet. 1998 Sep;7(9):1475-83 [9700203.001]
  • [Cites] Lancet. 1998 Aug 29;352(9129):704-5 [9728990.001]
  • [Cites] Arch Dermatol Res. 1998 Jul;290(7):367-74 [9749991.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Jun;9(2):153-65 [9754709.001]
  • [Cites] Curr Biol. 1998 Sep 24;8(19):1058-68 [9768360.001]
  • [Cites] J Urol. 1998 Nov;160(5):1850-5 [9783973.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3156-61 [9784490.001]
  • [Cites] Dev Biol. 1999 Jan 1;205(1):1-9 [9882493.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):138-41 [9916808.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):443-7 [10067911.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 13;257(2):596-603 [10198257.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Development. 1999 Aug;126(16):3693-701 [10409514.001]
  • [Cites] Hum Mol Genet. 1999 Sep;8(9):1769-77 [10441342.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11895-9 [10518547.001]
  • [Cites] Dermatology. 1999;199(3):204-7 [10592398.001]
  • [Cites] Clin Exp Dermatol. 1999 Nov;24(6):461-3 [10606949.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):979-89 [10629055.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7852-9 [10630638.001]
  • [Cites] Development. 2000 Feb;127(3):483-92 [10631169.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2000 Jan 21;49(2):28-31 [10680601.001]
  • [Cites] J Invest Dermatol. 2000 Jun;114(6):1075-84 [10844548.001]
  • [Cites] Endocr Rev. 2000 Aug;21(4):363-92 [10950157.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5386-9 [11034076.001]
  • [Cites] Hautarzt. 2000 Sep;51(9):685-7 [11057397.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 2;277(3):643-9 [11062007.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):1029-34 [11069186.001]
  • [Cites] Cell. 2000 Oct 27;103(3):371-4 [11081624.001]
  • [Cites] Cell. 2000 Nov 22;103(5):745-55 [11114331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14536-41 [11121055.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):330-8 [11180011.001]
  • [Cites] Dev Biol. 2001 Mar 1;231(1):47-62 [11180951.001]
  • [Cites] Bioessays. 2001 Mar;23(3):251-60 [11223882.001]
  • [Cites] J Bone Miner Res. 2001 Apr;16(4):705-12 [11315998.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):633-40 [11348449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7182-7 [11390973.001]
  • [Cites] Br J Nutr. 2005 Feb;93(2):175-7 [15788109.001]
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1119-26 [15955085.001]
  • [Cites] Development. 2005 Aug;132(15):3537-48 [15975938.001]
  • [Cites] Peptides. 2006 Feb;27(2):413-20 [16309786.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):561-5 [16354263.001]
  • [Cites] Cell. 2006 Jan 13;124(1):35-46 [16413480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6684-9 [11997436.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1446-65 [12080084.001]
  • [Cites] Eur J Dermatol. 2002 Sep-Oct;12(5):496-8 [12370145.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):869-78 [12410695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2266-71 [12591959.001]
  • [Cites] Dev Biol. 2003 Jan 15;253(2):165-74 [12645922.001]
  • [Cites] J Invest Dermatol. 2003 Jul;121(1):20-7 [12839559.001]
  • [Cites] Ann N Y Acad Sci. 2003 Jun;994:154-61 [12851311.001]
  • [Cites] Am J Hum Genet. 2003 Oct;73(4):939-47 [12900791.001]
  • [Cites] Acta Derm Venereol. 2003;83(4):300-1 [12926808.001]
  • [Cites] Exp Dermatol. 2003 Aug;12(4):480-9 [12930306.001]
  • [Cites] J Invest Dermatol. 1958 Mar;30(3):99-125 [13525782.001]
  • [Cites] Pediatr Dermatol. 2003 Sep-Oct;20(5):443-6 [14521567.001]
  • [Cites] Development. 2003 Nov;130(22):5493-501 [14530295.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1310-22 [14576152.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2173-8 [14633591.001]
  • [Cites] Gene. 2003 Dec 11;322:175-85 [14644509.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Development. 2004 Mar;131(6):1289-98 [14960493.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1692-700 [15199404.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13(19):2313-24 [15282208.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1506-7 [15567848.001]
  • [Cites] Development. 2005 Jan;132(2):335-44 [15604099.001]
  • [Cites] Exp Dermatol. 2005 Feb;14(2):143-52 [15679586.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):333-8 [15781674.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):877-85 [15854025.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 [15863030.001]
  • [Cites] J Am Acad Dermatol. 2005 Jul;53(1):173-4 [15965448.001]
  • [Cites] J Lipid Res. 2005 Dec;46(12):2624-35 [16162944.001]
  • [Cites] J Dtsch Dermatol Ges. 2003 Jul;1(7):535-46 [16295039.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1190-9 [16354189.001]
  • [Cites] FASEB J. 2006 Feb;20(2):395-7 [16354720.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):839-45 [16424016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4505-10 [16537363.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1226-32 [16575389.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21052-61 [16728399.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1042-51 [16778789.001]
  • [Cites] J Invest Dermatol. 2006 Sep;126(9):1966-75 [16912693.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1341-3 [17076721.001]
  • [Cites] Development. 2007 Feb;134(3):557-65 [17202188.001]
  • [Cites] Development. 2007 Feb;134(4):723-34 [17215304.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):285-90 [17264678.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Feb;5(2):110-7 [17274777.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] J Cutan Pathol. 2007 Apr;34(4):338-41 [17381805.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):247-56 [17448569.001]
  • [Cites] Clin Exp Dermatol. 2007 Sep;32(5):488-92 [17509056.001]
  • [Cites] J Cell Physiol. 2007 Sep;212(3):796-806 [17516543.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1145-50 [17694057.001]
  • [Cites] Traffic. 2007 Dec;8(12):1854-72 [17944804.001]
  • [Cites] Pediatr Dermatol. 2007 Sep-Oct;24(5):534-5 [17958804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19802-7 [18056630.001]
  • [Cites] Plast Reconstr Surg. 2008 Jan;121(1):218-24 [18176224.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1397-9 [18410418.001]
  • [Cites] Mol Biosyst. 2008 Jun;4(6):643-53 [18493663.001]
  • [Cites] Pediatr Res. 2008 Jun;63(6):662-6 [18520331.001]
  • [Cites] Horm Res. 2008;70(5):257-67 [18824863.001]
  • [Cites] J Invest Dermatol. 2009 Aug;129(8):1868-77 [19225542.001]
  • [Cites] Cutis. 1993 Oct;52(4):205-8 [8261804.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1074-8 [8302834.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):417-29 [8320264.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):524-8 [8381804.001]
  • [Cites] Dev Biol. 1993 Aug;158(2):475-86 [8393815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11874-8 [8524866.001]
  • [Cites] Am J Clin Nutr. 2001 Jul;74(1):96-100 [11451723.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3195-201 [11698404.001]
  • (PMID = 20436882.001).
  • [ISSN] 1938-1980
  • [Journal-full-title] Dermato-endocrinology
  • [ISO-abbreviation] Dermatoendocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2835907
  • [Keywords] NOTNLM ; Apert syndrome / acne / comedogenesis / fibroblast growth factor receptor-2 / fibroblast growth factors / insulin / insulin-like growth factor-1 / interleukin-1α / nevus comedonicus / sebogenesis / unilateral acneiform nevus
  •  go-up   go-down


3. Lukasiewicz E, Martel J, Roujeau JC, Flahault A: [Dermatology in private practice in France in 2000]. Ann Dermatol Venereol; 2002 Nov;129(11):1261-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La dermatologie libérale en France métropolitaine en 2000.
  • Our objective was to identify the skin disorders most commonly diagnosed by office-based dermatologists.
  • We also documented the severity of these skin disorders, as reflected by the repercussions on patient's everyday life, and the way physicians managed patients.
  • DESIGN: We carried out a one-day survey of visits to a randomly selected sample of 900 French office-based dermatologists.
  • RESULTS: Office-based dermatologists saw 6411 patients with 7839 skin disorders during the survey.
  • Office-based dermatologists mostly managed warts, acne, nevus, dermatitis, malignancies and pre-malignancies, fungal infection and psoriasis.
  • Half of the patients received topical treatment, 20.5 p. 100 a systemic drug and 40 p. 100 a minor surgical procedure (including cryotherapy).
  • CONCLUSION: Although dermatologists frequently see benign skin disorders such as warts or nevus, more severe diseases represent an important part of their activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12514513.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Vabres P: [What's new in pediatric dermatology?]. Ann Dermatol Venereol; 2008 Dec;135 Suppl 7:S343-53
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Quoi de neuf en dermatologie pédiatrique?
  • The main selected articles in pediatric dermatology covered the following topics: development and maturation of the epidermal barrier in the neonate, iatrogenic events in the neonatal ICU, diagnostic value of minor birthmarks, complications, risk factors and treatment of hemangiomas, coagulopathy in venous malformations, epidemiology and dermoscopy of congenital and acquired melanocytic nevi in childhood, growth of the body surface area, new pathogenic concepts and treatment in atopic dermatitis, the impact of filaggrin deficiency, hereditary factors in Kawasaki disease, severe and drug resistant cases, management of juvenile dermatomyositis, treatment of childhood psoriasis with biologics, the new classification of epidermolysis bullosa and therapeutic approach with cell therapy, neurological impairment in xeroderma pigmentosum, behavioural anomalies in X-linked ichthyosis, guidelines for neurofibromatosis type I, the genetics of an hereditary hypotrichosis, infantile acne, rosacea in childhood, mast cell disease management and, last but not least, treatment of hair lice with silicone.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Dermatology / trends. Pediatrics / trends. Skin Diseases / drug therapy. Skin Diseases / genetics
  • [MeSH-minor] Acne Vulgaris / drug therapy. Acne Vulgaris / genetics. Child. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / genetics. Dermatomyositis / drug therapy. Dermatomyositis / genetics. Epidermolysis Bullosa / drug therapy. Epidermolysis Bullosa / genetics. Hemangioma / drug therapy. Hemangioma / genetics. Humans. Hypotrichosis / drug therapy. Hypotrichosis / genetics. Ichthyosis / drug therapy. Ichthyosis / genetics. Mastocytosis / drug therapy. Mastocytosis / genetics. Mucocutaneous Lymph Node Syndrome / drug therapy. Mucocutaneous Lymph Node Syndrome / genetics. Neurofibromatosis 1 / drug therapy. Neurofibromatosis 1 / genetics. Nevus, Pigmented / drug therapy. Nevus, Pigmented / genetics. Psoriasis / drug therapy. Psoriasis / genetics. Risk Factors. Rosacea / drug therapy. Rosacea / genetics. Xeroderma Pigmentosum / drug therapy. Xeroderma Pigmentosum / genetics

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264210.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dermatologic Agents
  • [Number-of-references] 90
  •  go-up   go-down


5. Gayl Schweitzer V: Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope; 2001 Jun;111(6):1091-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Aggressive nonmelanomatous skin tumors (basal cell carcinoma, squamous cell carcinoma, and Bowen's disease) of the head and neck often occur in Caucasian elderly patients because of prior history of radiation therapy for teenage acne and adenoid hypertrophy; severe solar-induced skin damage, basal cell nevus syndrome, and other genetic skin diseases; chemical carcinogen exposure; and drug-induced immunosuppression.
  • Photodynamic therapy (PDT) with photosensitizing agents selectively taken up by skin provides a primary or adjunct intraoperative option for treatment of this special group of cancer patients.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hematoporphyrin Photoradiation. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404627.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


6. Deliduka SB, Kwong PC: Treatment of Nevus comedonicus with topical tazarotene and calcipotriene. J Drugs Dermatol; 2004 Nov-Dec;3(6):674-6
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Nevus comedonicus with topical tazarotene and calcipotriene.
  • Nevus comedonicus is a rare developmental defect of the pilosebaceous unit.
  • It is also thought to be a variant of epidermal nevus.
  • We present a case of a 7-year-old boy with bilateral nevus comedonicus who experienced cosmetic improvement with topical tazarotene and calcipotriene cream.
  • [MeSH-major] Calcitriol / analogs & derivatives. Facial Dermatoses / drug therapy. Nevus, Pigmented / drug therapy. Sweat Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Child. Dermatologic Agents / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Nicotinic Acids / administration & dosage

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624751.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Nicotinic Acids; 143NQ3779B / calcipotriene; 81BDR9Y8PS / tazarotene; FXC9231JVH / Calcitriol
  •  go-up   go-down


7. Guldbakke KK, Khachemoune A, Deng A, Sina B: Naevus comedonicus: a spectrum of body involvement. Clin Exp Dermatol; 2007 Sep;32(5):488-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naevus comedonicus: a spectrum of body involvement.
  • Naevus comedonicus (NC) is a rare developmental anomaly, with < 200 cases reported in the literature.
  • It usually occurs on the face, neck or chest, appearing as groups of closely arranged dilated follicular openings with keratin plugs.
  • [MeSH-major] Nevus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermabrasion / methods. Dermatologic Agents / therapeutic use. Female. Humans. Male. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509056.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents
  • [Number-of-references] 34
  •  go-up   go-down


8. Ho SG, Chan HH: The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol; 2009;10(3):153-68
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases.
  • The Asian patient with Fitzpatrick skin types III-V is rarely highlighted in publications on cutaneous disorders or cutaneous laser surgery.
  • However, with changing demographics, Asians will become an increasingly important group in this context.
  • Although high melanin content confers better photoprotection, photodamage in the form of pigmentary disorders is common.
  • Melasma, freckles, and lentigines are the epidermal disorders commonly seen, whilst nevus of Ota and acquired bilateral nevus of Ota-like macules are common dermal pigmentary disorders.
  • Bleaching agents, chemical peels, intense pulsed light (IPL) treatments, and fractional skin resurfacing have all been used with some success for the management of melasma.
  • Dermal pigmentary disorders are better targeted by QS ruby, QS alexandrite, and QS 1064-nm Nd:YAG lasers, but hyper- and hypopigmentation may occur.
  • For management of severe degrees of photoaging, fractional resurfacing is useful for wrinkle and pigment reduction, as well as acne scarring.
  • Acne, which is common in Asians, can be treated with topical and oral antibacterials, hormonal treatments, and isotretinoin.
  • Fractional skin resurfacing is very useful for improving the appearance of acne scarring.
  • Esthetic enhancement procedures such as botulinum toxin type A and fillers are becoming increasingly popular.
  • [MeSH-minor] Botulinum Toxins, Type A / therapeutic use. Cosmetic Techniques. Dermatologic Surgical Procedures. Humans. Pigmentation Disorders / ethnology. Pigmentation Disorders / therapy. Rejuvenation. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19354330.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 125
  •  go-up   go-down


9. Alpsoy E, Durusoy C, Ozbilim G, Karpuzoğlu G, Yilmaz E: Nevus comedonicus syndrome: a case associated with multiple basal cell carcinomas and a rudimentary toe. Int J Dermatol; 2005 Jun;44(6):499-501
Hazardous Substances Data Bank. BENZOYL PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevus comedonicus syndrome: a case associated with multiple basal cell carcinomas and a rudimentary toe.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis. Toes / abnormalities
  • [MeSH-minor] Adult. Amoxicillin-Potassium Clavulanate Combination / therapeutic use. Benzoyl Peroxide / therapeutic use. Cryosurgery. Dermatologic Agents / therapeutic use. Drug Therapy, Combination / therapeutic use. Humans. Male. Syndrome. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941441.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 5688UTC01R / Tretinoin; 74469-00-4 / Amoxicillin-Potassium Clavulanate Combination; W9WZN9A0GM / Benzoyl Peroxide
  •  go-up   go-down


10. Wakahara M, Kiyohara T, Kumakiri M, Kuwahara H, Fujita T: Bilateral nevus comedonicus: efficacy of topical tacalcitol ointment. Acta Derm Venereol; 2003;83(1):51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral nevus comedonicus: efficacy of topical tacalcitol ointment.
  • [MeSH-major] Dermatologic Agents / administration & dosage. Dihydroxycholecalciferols / administration & dosage. Nevus / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12636024.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Dihydroxycholecalciferols; 0 / Ointments; 60965-80-2 / 1 alpha,24-dihydroxyvitamin D3
  •  go-up   go-down


11. Makhado DA: Dermatological conditions in young adults (20-35 years)--part 1. SADJ; 2007 May;62(4):188-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Skin Diseases / drug therapy
  • [MeSH-minor] Acne Keloid / drug therapy. Acne Keloid / pathology. Acne Vulgaris / drug therapy. Acne Vulgaris / pathology. Adult. Condylomata Acuminata / pathology. Dysplastic Nevus Syndrome / pathology. Dysplastic Nevus Syndrome / surgery. Eczema, Dyshidrotic / drug therapy. Eczema, Dyshidrotic / pathology. Female. Humans. Lupus Erythematosus, Discoid / drug therapy. Lupus Erythematosus, Discoid / pathology. Male. Melanosis / drug therapy. Melanosis / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907589.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] South Africa
  • [Number-of-references] 1
  •  go-up   go-down


12. Bordel MT, Miranda A: [Unilateral nevus comedonicus: efficacy after treatment with 12% ammonium lactate]. Actas Dermosifiliogr; 2006 Mar;97(2):150
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilateral nevus comedonicus: efficacy after treatment with 12% ammonium lactate].
  • [Transliterated title] Nevo comedoniano unilateral: eficacia tras el tratamiento con lactato amónico al 12%.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Lactic Acid / therapeutic use. Nevus, Pigmented / drug therapy. Quaternary Ammonium Compounds / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595123.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Quaternary Ammonium Compounds; 33X04XA5AT / Lactic Acid
  •  go-up   go-down






Advertisement